VACCINE AGAINST BOVINE LEUKEMIA VIRUS

The vaccine against bovine leukemia virus (BLV) contains a peptide fraction, or a recombinant virus which express it, which includes the envelope glycoprotein gp51 of BLV virus and which leads to a high degree of neutralizing antibody formation. The gp51 glycoprotein is associated with a transmembra...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Hauptverfasser:	DANIEL GEORGES JOSEPH GHISLAIN PORTETELLE, ARSENE LEON GHISLAIN BURNY, VERONIQUE JOSETTE JACQUELINE MARIE VONECHE
Format:	Patent
Sprache:	eng
Schlagworte:	BEER BIOCHEMISTRY CHEMISTRY COMPOSITIONS THEREOF CULTURE MEDIA ENZYMOLOGY HUMAN NECESSITIES HYGIENE MEDICAL OR VETERINARY SCIENCE METALLURGY MICROBIOLOGY MICROORGANISMS OR ENZYMES MUTATION OR GENETIC ENGINEERING ORGANIC CHEMISTRY PEPTIDES PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES PROPAGATING, PRESERVING OR MAINTAINING MICROORGANISMS SPIRITS VINEGAR WINE
Online-Zugang:	Volltext bestellen
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Beschreibung
Zusammenfassung:	The vaccine against bovine leukemia virus (BLV) contains a peptide fraction, or a recombinant virus which express it, which includes the envelope glycoprotein gp51 of BLV virus and which leads to a high degree of neutralizing antibody formation. The gp51 glycoprotein is associated with a transmembrane glycoprotein or a specific monoclonal antibody of one of the epitopes of gp51, so that the gp51 glycoprotein is restored to its native configuration in which epitopes F, G and H are present, these epitopes being responsible for the biological activity of BLV virus, in a pharmaceutical vehicle or excipient such as those which are used to constitute vaccines.